Feb 27 |
Denali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial Results
|
Feb 27 |
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
|
Feb 27 |
Denali Therapeutics Announces $500 million Private Placement Equity Financing
|
Feb 27 |
Denali, fresh off study setback, gets $500M lift
|
Feb 16 |
Denali slips as Sanofi fails in mid-stage trial for ALS therapy
|
Feb 16 |
UPDATE 1-Denali-Sanofi's ALS drug fails to meet main goal of mid-stage trial
|
Feb 16 |
ALS drug from Denali, Sanofi falls short in mid-stage study
|
Feb 7 |
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™
|
Feb 1 |
Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™
|
Jan 26 |
Denali's (DNLI) Pipeline Progresses Despite Stiff Competition
|